Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure : A Longitudinal Analysis
Miñana, Gema (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Lorenzo, Miguel (Hospital Clínic Universitari (València))
Ramirez de Arellano, Antonio (HEOR, Viforpharma Group, Zurich, Switzerland)
Wächter, Sandra (Medical Department, Viforpharma Group, Zurich, Switzerland)
De la Espriella, Rafael (CIBER Cardiovascular, Madrid)
Sastre, Clara (Hospital Clínic Universitari (València))
Mollar, Anna (Hospital Clínic Universitari (València))
Núñez, Eduardo (Hospital Clínic Universitari (València))
Bodi, Vicente (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Sanchis, Juan (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Bayés-Genís, Antoni (Universitat Autònoma de Barcelona. Departament de Medicina)
Núñez, Julio (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)

Data:	2022
Resum:	In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with stable HF, patterns of treatment with intravenous iron, and clinical impact of intravenous iron on HF rehospitalization risk. We included 711 consecutive outpatients (4400 visits) with stable chronic HF from 2014 to 2019 (median [interquartile range] visits per patient: 2 [2-7]. ID was defined as serum ferritin <100 µg/L, or 100-299 µg/L with transferrin saturation (TSAT) < 20%. During a median follow-up of 2. 20 (1. 11-3. 78) years, ferritin and TSAT were measured at 2230 (50. 7%) and 2183 visits (49. 6%), respectively. ID was found at 846 (37. 9%) visits, with ferritin and TSAT available (2230/4400), and intravenous iron was administered at 321/4400 (7. 3%) visits; 233 (32. 8%) patients received intravenous iron during follow-up. After multivariate analyses, iron repletion at any time during follow-up was associated with a lower risk of recurrent HF hospitalization (hazard ratio [HR] = 0. 50, 95% confidence interval [CI] = 0. 28-0. 88; p = 0. 016). Thus, ID was a frequent finding in patients with HF, and its repletion reduced the risk of recurrent HF hospitalizations.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Iron deficiency ; Heart failure ; Prevalence ; Treatment
Publicat a:	Journal of clinical medicine, Vol. 11 (may 2022) , ISSN 2077-0383

DOI: 10.3390/jcm11092559
PMID: 35566684

10 p, 7.4 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats